CytoMed Therapeutics Limited: Business Overview, Financials & Competitive Analysis
CytoMed Therapeutics Limited scores 4/10 on the AskCyborg Cyborg Score (Mixed). Speculative Asia-focused cell therapy play with differentiated cost structure and expanding IP portfolio, but faces typical early biotech risks and capital requirements. Early-stage clinical company with validated technology (first-in-human trial ongoing since Nov 2024) and strategic geographic positioning. However, minimal cash runway disclosed into 2026, pre-revenue status, and small.
What is CytoMed Therapeutics Limited's industry? CytoMed Therapeutics Limited (cytomed.sg) operates in Biopharmaceutical/Cell Therapy - Oncology Immunotherapy. AskCyborg classifies CytoMed Therapeutics Limited under Biopharmaceutical/Cell Therapy - Oncology Immunotherapy in its company registry.
CytoMed is a Singapore-based clinical stage biopharmaceutical company focused on developing novel affordable donor-derived, cell-based allogeneic immunotherapies for cancer and aging-related diseases. Incorporated in ...
Cyborg Score thesis
Speculative Asia-focused cell therapy play with differentiated cost structure and expanding IP portfolio, but faces typical early...
Read the full analyst-debate transcript →Get the Latest CytoMed Therapeutics Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCytoMed Therapeutics Limited Overview
Pro stress-test →CytoMed is a Singapore-based clinical stage biopharmaceutical company focused on developing novel affordable donor-derived, cell-based allogeneic immunotherapies for cancer and aging-related diseases. Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency. The company is positioned to capitalize on Asia's cost advantages and large patient populations.
Strategic Profile
Pro stress-test →CytoMed intends to be among early pioneers of cellular immunotherapy treatment modalities in the ASEAN region and North Asia, leveraging Asia's low-cost infrastructure and talents to make affordable GMP-grade immune cells. The company recently completed acquisition of allogeneic gamma delta T cell technology (TCB-002) from TC BioPharm Limited in November 2025, strengthening its platform. CytoMed is located in the heart of a new special economic zone established in early 2025 by Singapore and adjacent State of Johor, Malaysia.
Competitive Landscape
Pro stress-test →Cellular treatment is gaining recognition and acceptance as another treatment modality to treat cancer patients with unmet needs. Key competitors in allogeneic CAR-T and cell therapy space include Juno Therapeutics (Beyer), Allogene Therapeutics, and established autologous CAR-T players like Gilead/Kite. CytoMed's differentiation lies in off-the-shelf (allogeneic) approach and cost structure targeting ASEAN/Asia.
Industry Context
CytoMed Therapeutics Limited operates in Biopharmaceutical/Cell Therapy - Oncology Immunotherapy.
Key facts
Founded: 2018 · Headquarters: Singapore, Singapore · Employees: 43 · Market cap: $12.6M